The Tough Tech problem we are solving
ADCs, bispecifics, CAR-T therapies, and radioligands all work the same way at their core: they tether a killing mechanism to a protein expressed on the surface of a tumor cell. The therapy's safety and effectiveness depend entirely on how selective that surface target is. A target that's also present on healthy tissue means the same tethered killing that hits the tumor damages normal cells too. Finding enough cancer-selective surface targets to aim these therapies at has been the field's bottleneck.
About our solution
Rubik built Oncolinkage, a computational approach that finds proteins whose surface expression on tumor cells becomes selectively dysregulated because of their genomic linkage to the mutations driving that tumor, the same disruption that gives the platform its name. Its screens have already identified more than 30 of these targets, most represented in breast, lung, prostate, and pancreatic cancers, each one suited to ADC, bispecific, CAR-T, or radioligand therapies. Rubik is now advancing five binders and their associated CARs against five of these targets, each dysregulated across a wide range of tumor types. A separate binder platform generates leads for the CAR-T and radioligand programs specifically.